Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults. The recommendations also apply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results